Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian groups try to lift EU-India trade deal secrecy after EC sued by campaigners

This article was originally published in Scrip

Executive Summary

Public interest and patients' groups in India have lauded moves by transparency campaigners in Europe to sue the European Commission over inadequate disclosures concerning the proposed free trade agreement (FTA) with India, backing it with their own efforts to lift the veil of secrecy surrounding the negotiations.

You may also be interested in...



Purple Patch: US Approval For Cipla's Gx Albuterol, Staggered Supplies Planned

Cipla gets US FDA go-ahead earlier than anticipated for first generic of Merck’s Proventil, setting the stage for increased competition in the albuterol segment, where demand is up amid the coronavirus pandemic.

COVID-19 Lock-Down: India Pharma Manufacturing Limps Along Amid Challenges

Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.

India Keeps Door Ajar For Hydroxychloroquine Exports, Drug Makers Geared Up

Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.

Topics

UsernamePublicRestriction

Register

SC011904

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel